Speakers

Speakers by Track

Plenary

Preclinical and Translational Immuno-Oncology

Immunomodulatory Approaches

CARs, TILs, TCRs

Biomarkers for Immuno-Oncology

Combination Immunotherapy

Bispecific Antibody Design and Applications


Plenary

Stanley Riddell, MD, Scientific Director, Clinical Research, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine

Roy D. Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharpe & Dohme


Preclinical and Translational Immuno-Oncology

Carlo Boutton, PhD, Head Nanobody Explorative Technologies, Discovery, Ablynx - Sanofi

Catarina Brito, PhD, Lab Head, Advanced Cell Models Lab, Animal Cell Technology Unit, iBET Catarina

Sara Colombetti, PhD, Global Head of Oncology Discovery Pharmacology, Pharma Research and Early Development (pRED), Roche Innovation Center Zurich

Lindy Durrant, PhD, Professor of Cancer immunotherapy, University of Nottingham; CSO, Scancell Ltd

Andrew Exley, PhD, Medical Assessor, Biologicals and Biotechnology Unit, MHRA

Denise Faustman, MD, PhD, Director of Immunobiology, Medicine, Harvard Medical School/Massachusetts General Hospital

Melanie Glossop, BSc, CChem, FRSC, Head of Chemistry, Centauri Therapeutics

Elizabeth Hardaker, PhD, Associate Director & Head, Oncology In Vivo Pharmacology Group, AstraZeneca

Russell W. Jenkins, MD, PhD, Assistant Professor, MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School

Tony Ng, FMEDSCI, MB, ChB, MRCP, FRCPath, PhD, Head of School of Cancer and Pharmaceutical Sciences, King’s College London, CRUK City of London Centre Executive Member, Richard Dimbleby Chair of Cancer Research, Group Leader, KCL Breast Cancer Now Research Unit, Director, KCL and UCL Comprehensive Cancer Imaging Centre, Chair of Molecular Oncology, UCL Cancer Institute

Stefan Ries, PhD, Global Head of External Innovation, Oncology, pRED Oncology, Roche Pharma, Roche Innovation Center Munich

Armin Sepp, PhD, Scientific Leader and GSK Fellow, IVIVT DMPK Modelling, GlaxoSmithKline

Eric Smith, PhD, Senior Director, Bispecific Antibodies, Regeneron Pharmaceuticals

Elena Spanjaard, PhD, Global Head of Regulatory Affairs, Celyad


Immunomodulatory Approaches

Stephen A. Beers, PhD, Professor of Immunology and Immunotherapy, Centre for Cancer Immunology, Cancer Sciences Unit, University of Southampton

Laura Codarri Deak, PhD, Principal Scientist, Cancer Immunotherapy, Roche Pharmaceutical Research and Early Development

Mark Cragg, PhD, Professor, Experimental Cancer Biology, Antibody & Vaccine Group, Cancer Sciences Unit, University of Southampton

Tanja de Gruijl, PhD, Professor and Chair of Translational Tumor Immunology, Medical Oncology, VU University Medical Center Amsterdam

Jane Grogan, PhD, Head Adaptive Tumor Immunity & Principal Scientist, Cancer Immunology, Genentech

Sophia N. Karagiannis, BA, MS, PhD, Reader, Translational Cancer Immunology, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London

Roman Kischel, MD, Director Research & Early Development Lead, Amgen Research Munich GmbH

Manfred Kraus, PhD, Director In Vivo Pharmacology & Oncology, In Vivo Pharmacology & Oncology, Pfizer

James Legg, PhD, Senior Vice President, Research, Crescendo Biologics

Jeanette Leusen, PhD, Associate Professor and Head Immunotherapy Group, Translational Immunology, University Medical Centre Utrecht

Michelle Morrow, PhD, Vice President, Preclinical Translational Pharmacology, F-star

Dario Neri, PhD, Professor, Biomacromolecules, Chemistry and Applied Biosciences, ETH Zürich

Karin Enell Smith, PhD, Senior Scientist, Preclinical Development, Alligator Bioscience AB

Hans van der Vliet, MD, PhD, CSO, LAVA therapeutics; Medical Oncologist, Amsterdam UMC


CARs, TILs, TCRs

Hinrich Abken, PhD, Professor, Chair Gene-Immunotherapy, Regensburg Center for Interventional Immunology, University Regensburg

James Arnold, PhD, Professor, Cancer Cell Biology and Imaging, Kings College London

Renier Brentjens, MD, PhD, Director, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center; Professor, Pharmacology, Weill Cornell Graduate School of Medical Sciences

Jo Brewer, PhD, Vice President, Allogeneic Research, AdaptImmune

George Coukos, Full Professor and Director, Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL); Director, Lausanne Branch, Ludwig Institute of Cancer Research Chief, Service of Immuno-Oncology, CHUV

Phil Darcy, PhD, Professor, NHMRC Principal Research Fellow, Laboratory Head Cancer Immunotherapy, Peter MacCallum Cancer Centre

Reno Debets, PhD, Associate Professor, Laboratory of Tumor Immunology, PI, Medical Oncology, Erasmus MC-Cancer Institute

David E Gilham, PhD, Vice President, R&D, Celyad

Weidong Han, PhD, Professor, Biotherapeutic, Chinese PLA General Hospital, Beijing, China

Robert Hawkins, MB BS, MRCP, PhD, FRCP, CEO, Immetacyte Ltd.; Honorary Professor, Medical Oncology, University of Manchester

Daniel Irimia, MD, PhD, Associate Professor, Surgery, Harvard Medical School, Massachusetts General Hospital, USA

Michael Klichinsky, PharmD, PhD, Co-Founder, Vice President, Discovery, Carisma Therapeutics

Mark Lowdell, PhD, Director, Centre for Cell, Gene & Tissue Therapeutics, RFH; Professor, Cell & Tissue Therapy, University College London

John Maher, FRCPath, PhD, Consultant & Senior Lecturer, Immunology, Cancer Studies, King’s College London

Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine


Biomarkers for Immuno-Oncology

Edith Borcoman, MD, Medical Oncologist, Institut Curie, Paris

Tricia Cottrell, PhD, Assistant Professor, Pathology and Molecular Medicine, Queens University

Roxana Dronca, MD, Associate Professor of Oncology, Consultant and Chair, Division of Hematology-Oncology, Mayo Clinic

Darius M. Dziuda, PhD, Professor, Mathematical Sciences, Central Connecticut State University

Kenneth Emancipator, MD, Executive Medical Director, Companion Diagnostics and Translational Medicine, Merck Sharp and Dohme (MSD)

Bruno Gomes, DVM, PhD, Head of Oncology Biomarkers, Early Clinical Development Oncology, Roche Pharma Research and Early Development

Felix Faber, CEO and Founder, MindPeak GmbH

Lukas Heukamp, MB, PhD, Director Molecular Pathology, Molecular Pathology, Institut für Hämatopathologie Hamburg

Sheeba Irshad, MD, PhD, Senior Clinical Lecturer, Cancer and Pharmaceutical Sciences, Kings College London

Daniel R. Karlin, MD, MA, CEO, HealthMode, Inc.

Benedikt Kessler, PhD, Professor of Biochemistry and Life Science Mass Spectrometry, Nuffield Department of Medicine, University of Oxford

Graham Pockley, PhD, CEO, multimmune GmbH; Professor of Immunobiology, John van Geest Cancer Research Centre, Nottingham Trent University

Camelia Quek, PhD, Senior Scientist Postdoctoral Scientist, Cancer Immunotherapy & Biomarkers, Melanoma Institute Australia

Wouter Scheper, PhD, Senior postdoc, Molecular Oncology and Immunology, Netherlands Cancer Institute

Jo Van Ginderachter, PhD, VIB Group Leader, Tumor-host interactions, Lab of Cellular and Molecular Immunology, VIB-Vrije Universiteit Brussel


Combination Immunotherapy

John Bell Ottawa, PhD, Senior Scientist, Innovative Cancer Therapeutics, Ottawa Hospital Research Institute

Ivan Diaz Padilla, MD, PhD, Executive Medical Director, Global Clinical Development Lead ; DNA-damage repair program, Oncology Global Clinical Development, Ares Trading, S.A. [Merck Group]

Jakob Dupont, MD, MA, Chief Medical Officer, Gossamer Bio

Tina J. Hieken, MD, Associate Professor of Surgery, Mayo Clinic

Gordon J. Freeman, PhD, Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

Franco Marincola, PhD, Chief Scientific Officer, Refuge Biotechnologies

John Maher, MD, Consultant, Immunology, Kings College London

Philipp Müller, PhD, Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG

Karoline Schjetne, PhD, Vice President Scientific Affairs, Vaccibody

Dimitris Skokos, PhD, Director, Immunity & Inflammation, Regeneron Pharmaceuticals

Paul Song, MD, Chief Medical Officer, Translation Medicine, NKMax America


Bispecific Antibody Design and Applications

Roland Kontermann, PhD, Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart

Mark Throsby, PhD, CSO, Merus NV

Paul Widboom, PhD, Associate Director, Antibody Discovery, Adimab LLC

Marlon J. Hinner, PhD, Principal Scientist, Group Leader Phage Display, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich

Stefano Majocchi, PhD, Therapeutic Program Lead, Light Chain Bioscience

Matthew J. Bernett, PhD, Associate Director, Protein & Antibody Engineering, Xencor, Inc.

Maria Karasarides, PhD, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals

John Babcook, PhD, Senior Vice President, Discovery Research, Zymeworks

Julian Andreev, PhD, Research Fellow, Oncology & Angiogensis, Regeneron Pharmaceuticals, Inc.

Jamie Baker, PhD, Chemistry, University College London

Dimitris Skokos, PhD, Associate Director, Immunology & Inflammation, Regeneron Pharmaceuticals

James Legg, PhD, Senior Vice President, Research, Crescendo Biologics

Anne Mansson-Kvarnhammar, PhD, Senior Scientist, Alligator Bioscience AB

Mathieu Cinier, PhD, Scientific Director, Affilogic

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag